FDA Rep (CFSAC) on why understanding the aetiology and pathophysiology of ME/CFS is important (and why the UK MRC research strategy was flawed)
I thought this was interesting. It shows why research which helps to elucidate the aetiology and pathophysiology of ME/CFS is so important.
================================
http://www.hhs.gov/advcomcfs/meetings/minutes/cfsac20101013.html
CHRONIC FATIGUE SYNDROME ADVISORY COMMITTEE Oct 14, 2010
[..]
Contract that with what the UK's Medical Research Council Research Strategy (2003) recommends, where it prioritised areas other than understanding the aetiology and pathophysiology:
-----------
Many including myself feel the contents of this strategy was influenced by the following which was announced two weeks later in May
2003:
MRC Announces Two Trials To Assess CFS/ME Treatments (PACE Trial and FINE Trial)
http://bit.ly/etuNB5 i.e.
http://listserv.nodak.edu/cgi-bin/wa.exe?A2=ind0305C&L=CO-CURE&P=R795&I=-3
------------
Putting the two together and the fact that Medical Research Council has failed to fund grant applications that looked at the aetiology and pathophysiology of ME and CFS, one could say they are at least partly to blame for the lack of drugs available for the condition.
Anyway, the ME/CFS community can help by raising money itself either through donating or fund-raising as well as when possible and useful indulging in lobbying to ensure we get a fair share of research budgets.
I thought this was interesting. It shows why research which helps to elucidate the aetiology and pathophysiology of ME/CFS is so important.
================================
http://www.hhs.gov/advcomcfs/meetings/minutes/cfsac20101013.html
CHRONIC FATIGUE SYNDROME ADVISORY COMMITTEE Oct 14, 2010
[..]
[..]Marc W. Cavaille-Coll, MD, PhD, Medical Officer Team Leader, Division of Special Pathogens and Immunologic Drug Products
[..]Drug development activity for CFS remains fairly limited. Until there is a mechanism or etiology, or in vitro or in vivo models allowing researchers to select molecules might have an effect in this area, it is very difficult to start drug discovery and development. FDA remains interested in all the information heard today and will continue to follow the field.
===============Stated that there was a real identifying agent in the HIV virus, which made it easier to get drug approvals faster. We're dealing with a complex systemic disease in CFS which complicates things.
[Dr. Cavaille-Coll] said that they ... have seen little development in the area due to lack of understanding on the etiology and pathophysiology that allows companies to identify promising products.
They are welcome to anyone who has a promising product.
Contract that with what the UK's Medical Research Council Research Strategy (2003) recommends, where it prioritised areas other than understanding the aetiology and pathophysiology:
-----------
"In view of the probable multiplicity of potential causal factors and the widely disparate findings so far reported, the MRC CFS/ME Research Advisory Group considers that studies investigating causal pathways and mechanisms, whilst having merit, would not have the same immediate impact on increasing understanding of CFS/ME, nor reducing the suffering of patients. This is not say that such studies should be abandoned, rather that it is not an essential prerequisite to identify triggers and causal pathways in order to undertake research on CFS/ME."
Many including myself feel the contents of this strategy was influenced by the following which was announced two weeks later in May
2003:
MRC Announces Two Trials To Assess CFS/ME Treatments (PACE Trial and FINE Trial)
http://bit.ly/etuNB5 i.e.
http://listserv.nodak.edu/cgi-bin/wa.exe?A2=ind0305C&L=CO-CURE&P=R795&I=-3
------------
Putting the two together and the fact that Medical Research Council has failed to fund grant applications that looked at the aetiology and pathophysiology of ME and CFS, one could say they are at least partly to blame for the lack of drugs available for the condition.
Anyway, the ME/CFS community can help by raising money itself either through donating or fund-raising as well as when possible and useful indulging in lobbying to ensure we get a fair share of research budgets.